scholarly journals The Changing Paradigm in the Treatment of Structural Heart Disease and the Need for the Interventional Imaging Specialist

2016 ◽  
Vol 11 (2) ◽  
pp. 135
Author(s):  
Nina C Wunderlich ◽  
Harald Küx ◽  
Felix Kreidel ◽  
Ralf Birkemeyer ◽  
Robert J Siegel ◽  
...  

Percutaneous interventions in structural heart diseases are emerging rapidly. The variety of novel percutaneous treatment approaches and the increasing complexity of interventional procedures are associated with new challenges and demands on the imaging specialist. Standard catheterisation laboratory imaging modalities such as fluoroscopy and contrast ventriculography provide inadequate visualisation of the soft tissue or three-dimensional delineation of the heart. Consequently, additional advanced imaging technology is needed to diagnose and precisely identify structural heart diseases, to properly select patients for specific interventions and to support fluoroscopy in guiding procedures. As imaging expertise constitutes a key factor in the decision-making process and in the management of patients with structural heart disease, the sub-speciality of interventional imaging will likely develop out of an increased need for high-quality imaging.

ESC CardioMed ◽  
2018 ◽  
pp. 438-441
Author(s):  
Francesco F. Faletra ◽  
Laura A. Leo ◽  
Tiziano Moccetti ◽  
Mark J. Monaghan

Three-dimensional echocardiography (3DE) certainly represents one of the major innovations of the last decades. Nowadays, 3DE has achieved a well-established role in many fields of cardiovascular diseases. This chapter discusses the contribution of 3DE towards a more precise quantitative assessment of cardiac chambers, in refining the diagnosis of structural heart diseases, and in guiding catheter-based structural heart disease procedures. The last section discusses the evolving role of a novel imaging system that specifically fuses fluoroscopy and two/three-dimensional echocardiography on one screen and represents a new exciting approach to image guidance for structural heart disease interventions.


Author(s):  
Francesco F. Faletra ◽  
Laura A. Leo ◽  
Tiziano Moccetti ◽  
Mark J. Monaghan

Three-dimensional echocardiography (3DE) certainly represents one of the major innovations of the last decades. Nowadays, 3DE has achieved a well-established role in many fields of cardiovascular diseases. This chapter discusses the contribution of 3DE towards a more precise quantitative assessment of cardiac chambers, in refining the diagnosis of structural heart diseases, and in guiding catheter-based structural heart disease procedures. The last section discusses the evolving role of a novel imaging system that specifically fuses fluoroscopy and two/three-dimensional echocardiography on one screen and represents a new exciting approach to image guidance for structural heart disease interventions.


2010 ◽  
pp. 175-190
Author(s):  
Juan Carlos Kaski

Valvular heart disease 176 Mitral stenosis 177 Mitral regurgitation 178 Mitral valve prolapse 179 Aortic stenosis 180 Aortic regurgitation 182 Tricuspid disease 184 Pulmonary valve disease 186 Antithrombotic management in valve heart disease 187 Cardiomyopathy 188 The most common causes of 1° structural defects in the heart are valvular heart disease, heart muscle disease (cardiomyopathy), and congenital structural heart diseases. Less commonly, 2° heart damage may be caused by infection....


2021 ◽  
Vol 10 (16) ◽  
pp. 3696
Author(s):  
Carlo Lavalle ◽  
Sara Trivigno ◽  
Giampaolo Vetta ◽  
Michele Magnocavallo ◽  
Marco Valerio Mariani ◽  
...  

Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.


2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
K A Simonova ◽  
R B Tatarskiy ◽  
A V Kamenev ◽  
V S Orshanskaya ◽  
V K Lebedeva ◽  
...  

Abstract Background Although there is a tremendous improvement in mapping and ablation techniques over the last decades, the recurrence rate of ventricular tachycardia (VT) in patients with structural heart diseases following endo-epicardial catheter ablation remains high. Purpose To determine predictors of VT recurrence in patients with structural heart disease after combined endo-epicardial radiofrequency (RF) VT ablation. Methods This prospective single-center study included 39 patients (34 men and 5 women, mean age 49.6±16.0 years), who underwent endo-epicardial mapping and ablation of the VT substrate. Etiology of structural heart diseases included: previous myocardial infarction (n=15); non-ischemic cardiomyopathy (n=24: 15 – arrhythmogenic right ventricular cardiomyopathy (ARVC), 6 – myocarditis, 3 – unspecified). First-line epicardial access was performed in 16 patients, as a second approach – in 23 subjects. We evaluated total ventricular myocardial areas, epi- and endocardial areas with bipolar low voltage (<1.5mV), scar area (bipolar <0.5mV), and unipolar low voltage (<5.0mV) and transient (<8.0mV) areas; areas of late potential registration were evaluated. Ratios of transient, low amplite and late-potential areas were calculated for endo- and epicardial surfaces, bipolar and unipolar maps. The following procedural electrophysiology characteristics were considered: inducibility of clinical VT, the number and morphology of induced VT, QRS width on sinus rhythm and VT, tachycardia cycle length, pseudo-delta wave extant and width, internal activation time, intrisicoud deflection time, and RS length. Clinical data such as echocardiography parameters, comorbidity and antiarrhythmic drug therapy were also taken into account. VT recurrences were documented using ICD/CRT-D interrogation, event ECG monitoring. Follow-up included mandatory visits at 6 and 12 months and unscheduled visits. Results Epicardial late potentials were registered in 69% of cases before ablation. Epicardial RF applications were delivered in 67% of patients; while only endocardial RF applications (including cases with intended epicardial substrate modification by endocardial ablation) were present in 28% cases. Non-inducibility of any VT plus abatement of local abnormal electrical activity was achieved in 32 (82%) of cases. The ratio epi/endo bipolar areas <0.5mV was much higher in patients with vs without VT recurrence at 6 months (4.3 (IQR: 2.5; 8.2) vs 0.75 (IQR:0.4; 1.6), P=0.001). A strong negative correlation was found between the induced VT cycle length and the ratio epi/endo bipolar areas <0.5mV: the shorter induced VT cycle length -the larger the area of the epicardial low voltage area (r=−0,52). Conclusion Regardless of epicardial substrate modification, patients with a larger epicardial low voltage area are more likely to have VT recurrence at 6 months after index ablation. A shorter induced VT cycle length is associated with a larger epicardial low-voltage area. FUNDunding Acknowledgement Type of funding sources: None.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Paerregaard ◽  
J Kock ◽  
C Pihl ◽  
A Pietersen ◽  
K.K Iversen ◽  
...  

Abstract Background The QRS axis represents the sum of the amplitudes and orientation of the ventricular depolarization. In newborns, the QRS axis is generally directed downward and to the right and left axis deviation (LAD) may be associated with heart disease. Accurate interpretation of abnormalities in the QRS axis may facilitate early diagnosis of heart diseases in newborns. Purpose To describe the evolution of the QRS axis during the first four weeks of life and provide updated, digitalized, normal values from healthy newborns. Methods Electrocardiograms from 12,317 newborns (age 0–28 days) included in a regional, prospective, general population study from 2016–2018 were analyzed. Electrocardiograms were obtained and analyzed with a computerized algorithm with manual validation. The algorithm calculated the QRS mean axis using the net amplitudes of three leads I, II, and III. The four main QRS axis classifications were: “adult normal” axis (+1° to +90°), left axis deviation (LAD, 0° to −90°), right axis deviation (RAD, +91° to +180°), and extreme axis deviation (EAD, +181° to +270°). Echocardiograms were performed according to standard guidelines. Only newborns with an echocardiography excluding structural heart disease were included. Results Electrocardiograms from 12,317 newborns with a median age at examination of 12 days (52% boys) were included. The median QRS axis was 119° at the ages 0–7 days and shifted leftwards to 102° at the ages 22–28 days (p<0.001). We found that girls had significant less pronounced right axis deviation than boys (111° vs 117°, p<0.001) and that increasing gestational age was associated with more pronounced right axis deviation (104° vs 116°, p<0.05). Infant size did not affect the axis (p>0.05). Only 0.5% had LAD (0° to −90°) and 1.1% had an axis within the interval +240° to +30° indicating that a QRS axis in this expanded interval is unusual in healthy newborns. Conclusion The QRS axis showed a gradual leftward-shift during the first four weeks of life and was affected by sex and gestation age but unaffected by infant size. LAD occurred in only 0.5% of the newborns. Our data serve as updated reference values, which may facilitate clinical handling of newborns. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): This work was supported by the Danish Children Heart Foundation, Snedkermester Sophus Jacobsen and wife Astrid Jacobsen's foundation (Grant 19-R112-A5248-26048), the Research Council at Herlev-Gentofte Hospital and Toyota-Fonden, Denmark.


2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
S Younus ◽  
H Maqsood ◽  
A Gulraiz ◽  
MD Khan ◽  
R Awais

Abstract Funding Acknowledgements Type of funding sources: Other. Main funding source(s): Self Introduction Malignant ventricular arrhythmia contributes to approximately half of the sudden cardiac deaths. In common practice, echocardiography is used to identify structural heart diseases that are the most frequent substrate of VA. Identification and prognostication of structural heart diseases are very important as they are the main determinant of poor prognosis of ventricular arrhythmia. Purpose : The objective of this study is to determine whether cardiac magnetic resonance (CMR) may identify structural heart disease (SHD) in patients with ventricular arrhythmia who had no pathology observed on echocardiography. Methods : A total of 864 consecutive patients were enrolled in this single-center prospective study with significant ventricular arrhythmia. VA was characterized as >1000 ventricular ectopic beats per 24 hours, non-sustained ventricular arrhythmia, sustained ventricular arrhythmia, and no pathological lesion on echocardiography. The primary endpoint was the detection of SHD with CMR. Secondary endpoints were a composite of CMR detection of SHD and abnormal findings not specific for a definite SHD diagnosis. Results : CMR studies were used to diagnose SHD in 212 patients (24.5%) and abnormal findings not specific for a definite SHD diagnosis in 153 patients (17.7%). Myocarditis (n = 84) was the more frequent disease, followed by arrhythmogenic cardiomyopathy (n = 51), ischemic heart disease (n = 32), dilated cardiomyopathy (n = 17), hypertrophic cardiomyopathy (n = 12), congenital cardiac disease (n = 08), left ventricle noncompaction (n = 5), and pericarditis (n = 3). The strongest univariate and multivariate predictors of SHD on CMR images were chest pain (odds ratios [OR]: 2.5 and 2.33, respectively) and sustained ventricular tachycardia (ORs: 2.62 and 2.21, respectively). Conclusion : Our study concludes that SHD was able to be identified on CMR imaging in a significant number of patients with malignant VA and completely normal echocardiography. Chest pain and sustained ventricular tachycardia were the two strongest predictors of positive CMR imaging results. Abstract Figure. Distribution of different SHD


ESC CardioMed ◽  
2018 ◽  
pp. 2208-2211
Author(s):  
Bhupesh Pathik ◽  
Jonathan M. Kalman

Atrial flutter refers to an electrocardiographic (ECG) appearance of continuously undulating flutter waves without an isoelectric baseline. It represents a heterogeneous group of atrial arrhythmias characterized by a macroreentrant mechanism. However, focal atrial tachycardia, especially if rapid and in the context of underlying structural heart disease or prior atrial surgery, may also cause a similar ECG appearance. A definition based on the underlying macroreentrant mechanism is therefore preferred particularly in the current era of three-dimensional electroanatomical mapping which allows detailed anatomical delineation of the circuit location. The clinical presentations of atrial macroreentry are variable and are influenced by ventricular response rate, presence of underlying structural heart disease, prior atrial surgery, or medications. The purpose of this chapter is to describe the different clinical presentations of this arrhythmia as well as its classification according to underlying mechanism. In addition, the clinical presentation of atrial macroreentry in special clinical situations is discussed. These include (1) the relationship between atrial fibrillation and cavotricuspid isthmus-dependent atrial macroreentry, (2) the organization of atrial fibrillation into atrial macroreentry with flecainide treatment, and (3) the association between atrial macroreentry and tachycardia-induced cardiomyopathy.


ESC CardioMed ◽  
2018 ◽  
pp. 560-565
Author(s):  
Victoria Delgado

Computed tomography (CT) has become an important imaging tool to evaluate cardiac anatomy. This three-dimensional, isotropic imaging technique provides volumetric datasets with submillimetre tissue resolution that can be post-processed to define the cardiac structures. CT has become the mainstay imaging technique for selection of patients for, and planning of, transcatheter interventions for structural heart disease. Electrocardiographic-gated CT permits acquisition of cardiac datasets along the cardiac cycle enabling assessment of left and right ventricular function and valvular heart disease. In addition, the advent of three-dimensional printing technologies, which use three-dimensional patient-specific models frequently obtained from CT datasets, has opened a myriad of possibilities in terms of development of anatomical teaching tools, functional models to assess vessel and valve function, planning surgical or transcatheter interventions, and designing of transcatheter cardiac devices. This chapter reviews the role of CT in assessing cardiac morphology and function and valvular heart disease.


Sign in / Sign up

Export Citation Format

Share Document